Gerry Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gerry Guo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Lawrence Cunningham
The Westmead Institute for Medical Research, University of Sydney, Sydney, Australia
1 shared publication - Ava Larsen
Affiliation Centre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia
1 shared publication James Smith
Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publication- Keith Ong
Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publication - Kevin Danastas
Affiliation Centre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney, Westmead, Australia
1 shared publication Liane Papantoniou
Department of Ophthalmology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e271450
Treatment of spontaneous hyphema in Fuch’s heterochromic iridocyclitis with intravitreal anti-VEGF ranibizumab
Fuch’s heterochromic iridocyclitis (FHI) is a unilateral ocular condition characterised by low-grade anterior uveitis. Although the underlying aetiology remains unclear, proposed triggers include infections, autoimmune mechanisms and genetic predisposition. Amsler’s sign is a recognised complication of FHI whereby patients develop spontaneous hyphaema that is often self-limiting. Current management of FHI focuses on managing complications such as raised intraocular pressures (IOPs), secondary glaucoma and formation of cataracts rather than the inflammation itself. In this case report, we present a patient with FHI complicated by spontaneous hyphaema and acute-on-chronic ocular hypertension refractory to medical therapy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resultant reduction in IOP. Subsequent trabeculectomy was performed for definitive control of persistent chronic ocular hypertension. This case highlights anti-VEGF therapy as a potential adjunctive strategy in selected patients presenting with similar clinical challenges.
- 17 July 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (7) , e271450
Open AccessTreatment of spontaneous hyphema in Fuch’s heterochromic iridocyclitis with intravitreal anti-VEGF ranibizumab
Fuch’s heterochromic iridocyclitis (FHI) is a unilateral ocular condition characterised by low-grade anterior uveitis. Although the underlying aetiology remains unclear, proposed triggers include infections, autoimmune mechanisms and genetic predisposition. Amsler’s sign is a recognised complication of FHI whereby patients develop spontaneous hyphaema that is often self-limiting. Current management of FHI focuses on managing complications such as raised intraocular pressures (IOPs), secondary glaucoma and formation of cataracts rather than the inflammation itself. In this case report, we present a patient with FHI complicated by spontaneous hyphaema and acute-on-chronic ocular hypertension refractory to medical therapy. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) ranibizumab was used, which achieved rapid resolution of hyphaema with resultant reduction in IOP. Subsequent trabeculectomy was performed for definitive control of persistent chronic ocular hypertension. This case highlights anti-VEGF therapy as a potential adjunctive strategy in selected patients presenting with similar clinical challenges.
- Open Access
- 24 January 2022
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 18 (1) , e1010264
Herpes simplex virus-1 utilizes the host actin cytoskeleton for its release from axonal growth cones
Herpes simplex virus type 1 (HSV-1) has evolved mechanisms to exploit the host cytoskeleton during entry, replication and exit from cells. In this study, we determined the role of actin and the molecular motor proteins, myosin II and myosin V, in the transport and release of HSV-1 from axon termini, or growth cones. Using compartmentalized neuronal devices, we showed that inhibition of actin polymerization, but not actin branching, significantly reduced the release of HSV-1 from axons. Furthermore, we showed that inhibition of myosin V, but not myosin II, also significantly reduced the release of HSV-1 from axons. Using confocal and electron microscopy, we determined that viral components are transported along axons to growth cones, despite actin or myosin inhibition. Overall, our study supports the role of actin in virus release from axonal growth cones and suggests myosin V as a likely candidate involved in this process.
- 24 January 2022
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 18 (1) , e1010264
Open AccessHerpes simplex virus-1 utilizes the host actin cytoskeleton for its release from axonal growth cones
Herpes simplex virus type 1 (HSV-1) has evolved mechanisms to exploit the host cytoskeleton during entry, replication and exit from cells. In this study, we determined the role of actin and the molecular motor proteins, myosin II and myosin V, in the transport and release of HSV-1 from axon termini, or growth cones. Using compartmentalized neuronal devices, we showed that inhibition of actin polymerization, but not actin branching, significantly reduced the release of HSV-1 from axons. Furthermore, we showed that inhibition of myosin V, but not myosin II, also significantly reduced the release of HSV-1 from axons. Using confocal and electron microscopy, we determined that viral components are transported along axons to growth cones, despite actin or myosin inhibition. Overall, our study supports the role of actin in virus release from axonal growth cones and suggests myosin V as a likely candidate involved in this process.